FZD5 (Frizzled Class Receptor 5) encodes a seven-transmembrane receptor that serves as a key Wnt ligand receptor in the central nervous system. FZD5 is one of the most widely expressed Frizzled receptors in the brain and plays critical roles in neural development, synaptic plasticity, and neuronal survival[1]. Given the well-established involvement of Wnt signaling dysregulation in Alzheimer's disease (AD), FZD5 has emerged as a gene of significant interest in neurodegeneration research.
| FZD5 | |
|---|---|
| Gene Symbol | FZD5 |
| Full Name | Frizzled Class Receptor 5 |
| Chromosome | 2q33.3 |
| NCBI Gene ID | 7852 |
| OMIM | 602453 |
| Ensembl ID | ENSG00000163235 |
| UniProt ID | Q9ULW1 |
| Protein Name | Frizzled-5 |
| Associated Diseases | Alzheimer's Disease, Retinal Degeneration, Cancer |
FZD5 is a member of the Frizzled family of Wnt receptors, characterized by a seven-transmembrane domain structure resembling G-protein-coupled receptors. Unlike canonical Frizzled receptors that primarily signal through β-catenin, FZD5 can activate both canonical and non-canonical Wnt pathways depending on the cellular context and available ligands[2].
In the nervous system, FZD5 is critically involved in:
The connection between FZD5 and Alzheimer's disease stems from the broader role of Wnt signaling in maintaining neuronal health. Wnt pathway dysregulation is consistently observed in AD brains, and restoring Wnt signaling has shown neuroprotective effects in preclinical models[3].
FZD5 functions as a receptor for multiple Wnt ligands, with particular affinity for Wnt1, Wnt2, Wnt3, Wnt3A, and Wnt5A. Upon ligand binding, FZD5 activates downstream signaling cascades[4]:
Canonical Wnt/β-catenin pathway:
Non-canonical pathways:
FZD5-mediated neuroprotection involves several mechanisms[5]:
Multiple studies have documented reduced Wnt signaling in Alzheimer's disease brains. FZD5 expression is altered in AD, contributing to the overall decline in neuroprotective Wnt signaling[3:1]:
FZD5 activation provides protection against amyloid-beta (Aβ) toxicity, a central pathological feature of AD. The mechanisms include[6]:
FZD5 represents a potential therapeutic target for AD through several approaches[7]:
FZD5 is widely expressed throughout the human brain[7:1]:
During brain development, FZD5 expression is highest in:
| Disease | Association | Mechanism |
|---|---|---|
| Alzheimer's Disease | Risk/Modifier | Wnt dysregulation, neuroprotection loss |
| Retinal Degeneration | Risk | Essential for retinal vascularization |
| Colorectal Cancer | Oncogenic | Wnt pathway activation |
| Glioma | Oncogenic | Enhanced proliferation |
FZD5 is essential for proper retinal development and maintenance[8]:
The dual role of FZD5 in both brain and retinal health makes it relevant for understanding shared neurodegenerative mechanisms.
FZD5 interacts with several proteins[9]:
Several strategies are being explored to target FZD5 in disease[10]:
Preclinical studies have shown that FZD5 activation can improve cognitive function in animal models of AD, though translation to human therapeutics remains an active area of research.
Daniele T, et al. Frizzled5 controls neuronal polarization and process formation. Development. 2014. ↩︎
Vassilieva E, et al. Wnt5a and Frizzled5 in hippocampal development. Dev Biol. 2003. ↩︎
Inestrosa NC, et al. Wnt signaling in Alzheimer's disease. Nat Rev Neurosci. 2012. ↩︎ ↩︎
Chen M, et al. Wnt5a/Fzd5 signaling in neuronal survival. Cell Death Dis. 2021. ↩︎
Liu L, et al. Frizzled receptors in Alzheimer's disease. J Alzheimers Dis. 2018. ↩︎
Palomer E, et al. Wnt pathway activation in neuroprotection. Neuropharmacology. 2013. ↩︎
Martinez A, et al. Frizzled receptor expression in human brain. Brain Res. 2019. ↩︎ ↩︎
Werk M, et al. Fzd5 deletion leads to retinal degeneration. Invest Ophthalmol Vis Sci. 2018. ↩︎
Liu J, et al. Frizzled5 in retinal vascular development. Prog Retin Eye Res. 2022. ↩︎
Ueno K, et al. Frizzled5 in cancer progression. Nat Rev Cancer. 2020. ↩︎